胃癌组织芯片中Ezrin蛋白的表达及意义

目的探讨细胞骨架蛋白Ezrin在胃癌组织芯片中的表达及临床意义。方法利用组织芯片技术和免疫组化Envision法检测Ezrin蛋白在385例胃癌（包括114例淋巴结未转移的胃癌和271例淋巴结转移的胃癌）及40例距肿瘤7cm的正常胃组织中Ezrin蛋白的表达情况。所有患者均经外科手术治疗，病理诊断明确，术前未经放、化疗。结果Ezrin蛋白在胃癌中的阳性率为64．9％（250／385），而在正常胃黏膜组织中的阳性表达率为5．0％（2／40），P〈0．05；在淋巴结未转移者中的阳性率为16．6％（64／114），在淋巴结转移者中的阳性率为48．3％（186／271），P〈0．05。Ezrin蛋白在淋巴结转移性胃癌中的高表达高于非转移性胃癌[40．0％（154／385）比14．8％（57／385），P〈0．05]；与胃癌仅侵犯至肌层者相比，胃癌侵犯至浆膜及浆膜外者Ezrin蛋白呈高表达[44．4％（171／385）比9．4％（36／385），P〈0．05]。结论胃癌组织中Ezrin蛋白的阳性表达明显高于正常胃组织，并与胃癌的浸润及转移相关。

Expression of Ezrin in gastric carcinoma and its clinicopathologic significance

Objective To investigate the expression of Ezrin protein in gastric carcinoma and its clinicopathologic significance. Methods The expression of Ezrin protein was detected by Envision immunohistochemical method in tissues-microarry （TMA）. There were 385 cases of gastric carcinoma [ without lymphatic metastasis （n = 114） and gastric carcinoma with lymphatic metastasis （n = 271 ） ]. 40 paraffin-embedded tissue blocks of normal gastric epithelium （ 〉7 cm away from the edge of the tumor） were selected as the control group. All patients with gastric cancer were treated surgically and diagnosed histologically without preoperative chemotherapy or radiotherapy. Results The positive expression rates of Ezrin were 64.9% （250/385） in gastric carcinoma tissues and 5. 0% （ 2/40 ） in normal tissues ; the expression of Ezrin protein in gastric cancer was significantly higher than that in normal gastric mucosa（ P 〈 0.05 ） ; it was 16.6% （64/114） in gastric carcinoma tissues without lymph node metastasis and 48.3% （ 186/271 ） in those with lymph node metastasis. Ezrin protein expression was higher in metastatic gastric carcinoma than that in primary gastric carcinoma tissues [ 40.0% （ 154/ 385 ）vs 14.8% （57/385）, P 〈 0.05 ]. Ezrin protein expression in gastric cancer invasion to serosa was higher than that in the muscle layer only [ 44.4% （ 171/385 ） vs 9.4% （ 36/385 ）, P 〈 0.05 ]. Conclusions Ezrin may contribute to the invasion and metastasis of gastric carcinoma through enhancing or up-regulating Ezrin orotein.